Pfizer-BioNTech COVID-19 vaccine information

This page contains documents relating specifically to the Pfizer BioNTech COVID-19 and Comirnaty® vaccine.

National protocol for Comirnaty® COVID-19 mRNA vaccine

National protocol for Comirnaty® 10 microgram/dose COVID-19 mRNA vaccine

National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) (withdrawn on 20 April 2022)


Pfizer BioNTech COVID-19 vaccine information - Regulatory approval of COVID-19 Pfizer BioNTech vaccine Regulatory approval of COVID-19 Pfizer BioNTech vaccine
Comirnaty® vaccine Patient Information Leaflet

COVID-19: vaccine Comirnaty® Patient Information Leaflet

COVID-19: vaccine Comirnaty® (10micrograms/dose) concentrate Patient Information Leaflet Children 5 to 11

Comirnaty® vaccine SPC

COVID-19: vaccine Comirnaty® 'SPC'

COVID-19: vaccine Comirnaty® (10micrograms/dose) concentrate 'SPC' Children 5 to 11

Pfizer BioNTech vaccine SPC

COVID-19: vaccine BNT162b2 'SPC'

Patient Group Direction for Comirnaty®

Patient Group Direction for Comirnaty® (Pfizer BioNTech)

Patient Group Direction for Comirnaty® (10micrograms/dose) concentrate for children 5-11 years

Patient Specific Direction Pfizer vaccine (for local adoption)

Individual Patient assessment to assist the creation of Patient Specific Direction for the administration of the Pfizer vaccine

Pfizer BioNTech vaccine Patient Information Leaflet

COVID-19: vaccine BNT162b2 Patient Information Leaflet
Pfizer Vaccine Ingredients

Pfizer Vaccine Ingredients

British Islamic Medical Association statement

British Islamic Medical Association: Position statement on the Pfizer/BioNTech COVID-19 vaccine


SPS Pfizer-BioNTech information

Information specific to Pfizer-BioNTech vaccine

Managing risks associated with the introduction of the Comirnaty vaccine for children 5 to 11 years old


Derby and Derbyshire CCG

Derby and Derbyshire CCG

Please click the button to navigate to our app

Redirect to app